Artificial Intelligence algorithms are used to identify “progeny” drugs that are similar to the “parents” already being tested against COVID-19. These algorithms assess similarity not only by the molecular make-up of the molecules, but also by the “context” in which specific functional groups are arrangedand/or by three-dimensional distribution of pharmacophores. The parent-progeny relationships span same-indication drugs (mostly antivirals) as well as those in which the “progenies” have different and perhaps less intuitive primary indications (e.g., immunosuppressant or anti-cancer progenies from antiviral parents). The “progenies” are either already approved drugs or medications in advanced clinical trials – should the currently tested “parent” medicines fail in clinical trials, these “progenies” could be, therefore, re-purposed against the COVID-19 on the timescales relevant to the current pandemic.
ORCID For Submitting Author0000-0001-6613-4261
Declaration of Conflict of InterestThe authors are owners and/or contractors of Allchemy, Inc. This being said, the authors declare no
financial interest in the current work.